Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarker

Project description

Cancer biomarkers for predicting treatment outcome

Drug effectiveness is often hampered by systemic cytotoxicity. Anti-cancer drugs exhibit adverse effects by damaging normal tissues and organs. Prodrugs that can be activated by specific stimuli to exert their pharmacological effect have emerged as safer options. CP-506 is such a prodrug that is activated by the low oxygen levels of tumours (hypoxia) known to promote cancer aggressiveness and therapy resistance. CP-506 causes DNA damage so tumours defective in DNA repair pathways are at a disadvantage. The mission of the ERC-funded ReverseTheAdvantage project is to develop a solution that can identify tumours that exhibit both hypoxia and defects in DNA damage repair to predict the efficacy of CP-506 treatment.

Fields of science

• natural sciences › computer and information sciences › software
• natural sciences › biological sciences › genetics › DNA
• natural sciences › biological sciences › genetics › mutation
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › immunology › immunotherapy

Programme(s)

• HORIZON.1.1 - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2022-POC2 - ERC PROOF OF CONCEPT GRANTS2

Call for proposal

ERC-2022-POC2

See other projects for this call

Funding Scheme

HORIZON-AG-LS - HORIZON Lump Sum Grant

Coordinator

UNIVERSITEIT MAASTRICHT

Net EU contribution

€ 150 000,00

Address

Minderbroedersberg 4
6200 MD Maastricht
Netherlands

Region

Limburg (NL) › Zuid-Limburg

Activity type

Higher or Secondary Education Establishments

Links

Other funding

No data